TABRECTA DIN 02527391
Status: Marketed
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Molecule: CAPMATINIB (CAPMATINIB HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | CAPMATINIB (CAPMATINIB HYDROCHLORIDE) 150 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EP01 CAPMATINIB |
| Original market date | 16-Sep-2022 |
| Current status date | 16-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CAPMATINIB (CAPMATINIB HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02527405 | TABRECTA | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | CAPMATINIB (CAPMATINIB HYDROCHLORIDE) 200 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30374 | 2022-05-26 | New Drug Submission (NDS) |